198 related articles for article (PubMed ID: 32694298)
21. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
Ludmir EB; Kachnic LA; Czito BG
Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial).
Murofushi KN; Itasaka S; Shimokawa M; Murakami Y; Yamamoto T; Nishimura Y; Kudo S; Sakamoto T; Ariga T; Ogo E; Taguchi K; Jingu K; Ogawa K
J Radiat Res; 2023 Jan; 64(1):154-161. PubMed ID: 36280895
[TBL] [Abstract][Full Text] [Related]
23. Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey.
Esin E; Yıldız F; Laçin Ş; Karakaş Y; Gültekin M; Dizdar Ö; Yalçın Ş
Turk J Gastroenterol; 2018 Jul; 29(4):411-418. PubMed ID: 30249555
[TBL] [Abstract][Full Text] [Related]
24. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
25. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
[TBL] [Abstract][Full Text] [Related]
27. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
28. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal.
Tomasoa NB; Meulendijks D; Nijkamp J; Cats A; Dewit L
Acta Oncol; 2016 Jun; 55(6):760-6. PubMed ID: 26878244
[TBL] [Abstract][Full Text] [Related]
31. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
[TBL] [Abstract][Full Text] [Related]
32. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.
Holliday EB; Morris VK; Johnson B; Eng C; Ludmir EB; Das P; Minsky BD; Taniguchi C; Smith GL; Koay EJ; Koong AC; Delclos ME; Skibber JM; Rodriguez-Bigas MA; You YN; Bednarski BK; Tillman MM; Chang GJ; Jennings K; Messick CA
Oncologist; 2022 Feb; 27(1):40-47. PubMed ID: 35305097
[TBL] [Abstract][Full Text] [Related]
33. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
34. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
[TBL] [Abstract][Full Text] [Related]
35. Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer.
Lerman J; Hennequin C; Etienney I; Abramowitz L; Goujon G; Gornet JM; Guillerm S; Aparicio T; Valverde A; Cattan P; Quéro L
Eur J Cancer; 2020 Dec; 141():143-151. PubMed ID: 33137590
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy.
Yucel S; Kadioglu H; Gural Z; Akgun Z; Saglam EK
J Cancer Res Ther; 2021; 17(1):51-55. PubMed ID: 33723132
[TBL] [Abstract][Full Text] [Related]
37. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis.
Neelis KJ; Kip DM; Speetjens FM; van der Linden YM
Radiat Oncol; 2022 Apr; 17(1):81. PubMed ID: 35443730
[TBL] [Abstract][Full Text] [Related]
38. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
39. Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study.
Elson JK; Kachnic LA; Kharofa JR
Cancer; 2018 Nov; 124(22):4383-4392. PubMed ID: 30329160
[TBL] [Abstract][Full Text] [Related]
40. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]